Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity

Cancer Commun (Lond). 2023 Oct;43(10):1178-1182. doi: 10.1002/cac2.12474. Epub 2023 Jul 31.

Authors

Zhenzhen Wang¹, Yang Lu¹, Yu Liu¹, Junli Mou¹, Xiaoyu Liu¹, Manling Chen¹, Ying Wang¹, Yingxi Xu¹, Qing Rao¹, Haiyan Xing¹, Kejing Tang¹, Zheng Tian¹, Bing Wang², Wei Qi², Min Wang¹, Shaowei Qiu¹, Dongsheng Xiong¹, Jianxiang Wang¹

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P. R. China.
² Novogene Co, Ltd, Beijing, P. R. China.

No abstract available

Publication types

Letter

Grants and funding